Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Pillow OEM for wellness brands Taiwan
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Ergonomic insole ODM support Vietnam
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Custom foam pillow OEM in Thailand
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Thailand pillow OEM manufacturer
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Insole ODM factory in Indonesia
Researchers re-analyzing public RNA sequencing data have uncovered nearly ten times more RNA viruses than previously known, including several new species of coronaviruses in unexpected places. The Serratus Project, led by Dr. Artem Babaian, re-analyzed RNA sequencing data, discovering nearly ten times more RNA viruses than previously known. A former UBC post-doctoral research fellow led an international research team in re-analyzing all public RNA sequencing data to uncover almost ten times more RNA viruses than were previously known, including several new species of coronaviruses in some unexpected places. This planetary-scale database of RNA viruses can help pave the way to rapidly identify virus spillover into humans, as well as those viruses that affect livestock, crops, and endangered species. Dr. Artem Babaian (he/him) is behind the Serratus Project collaboration. It published the stunning results of the research in the prestigious scientific journal Nature last week. The Power Behind the Serratus Project Working with the Cloud Innovation Centre, a public/private collaboration between UBC and Amazon Web Services, the Serratus Project was able to build a “ridiculously powerful” supercomputer on AWS equivalent in power to 22,500 CPUs, said Babaian. The supercomputer read through 20 million gigabytes of publicly available gene sequence data from 5.7 million biological samples around the world, searching for a specific gene that indicated the presence of an RNA virus. The samples have been collected and freely shared within the world research community over 13 years and include everything from ice-core samples to animal dung. Map of World Sequencing Data. Credit: Serratus Project Researchers with the Serratus Project found 132,000 RNA viruses (where just 15,000 were known previously) and nine new species of coronaviruses. Babaian estimates that without the CIC and the AWS Cloud, it would take a traditional supercomputer well over a year and hundreds of thousands of dollars to perform the 2,000 years of CPU time necessary for this analysis. Serratus accomplished it in 11 days for $24,000. Anticipating Pandemics Through Advanced Virus Tracking “We’re entering a new era of understanding the genetic and spatial diversity of viruses in nature, and how a wide variety of animals interface with these viruses. The hope is we’re not caught off guard if something like SARS-CoV-2—the novel coronavirus that causes COVID-19— emerges again. These viruses can be recognized more easily and their natural reservoirs can be found faster. The real goal is these infections are recognized so early that they never become pandemics,” said Babaian, who holds a PhD in medical genetics from UBC and is now a Banting Fellow at the University of Cambridge. “If a patient presents with a fever of unknown origin, once that blood is sequenced, you can now connect that unknown virus in the human to a way bigger database of existing viruses. If a patient, for example, presents with a viral infection of unknown origin in St. Louis, you can now search through the database in about two minutes, and connect that virus to, say, a camel in sub-Saharan Africa sampled in 2012.” Babaian, 32, had been conducting genetic research into cancer with BC Cancer when the COVID-19 pandemic hit and he switched gears. The work, which the understated Babaian says started as a “fun side project,” began March 3, 2020, when he and his climbing partner friend, UBC engineering student Jeff Taylor, sketched out the idea “on the back of a napkin,” said Babaian. “I should have kept that napkin,” he noted. Babaian approached UBC’s Cloud Innovation Centre for help shortly after. Serratus, named after Serratus Mountain in the Tantalus Range in British Columbia, which he and Taylor viewed during a climb in 2020, was born. Babaian recalled he was sitting on his wife’s nursing chair when the first results started to flash up on his laptop, indicating that Serratus was not only working, but producing data almost incomprehensibly fast. “It was probably the most exciting scientific period of my life,” he said. “There are two types of fun. Type 1 is smiling and fun. Type 2 is when you’re miserable while doing it but the memory shines, like rock climbing. In many ways Serratus is Type 2 fun. You just kind of have to believe it’s going to work out.” Collaboration with UBC’s Cloud Innovation Centre Babaian said he would not have been able to do this work without the support of the UBC Cloud Innovation Centre. “The Cloud Innovation Centre was really there unlocking the doors for us,” he said. “We had an idea and they brought in experts from their networks to make it come to life. Now the global community can benefit from all this previously untapped research.” “Artem approached us with an innovative vision. The power of the Cloud Innovation Centre is that we pair our in-house innovation and technology teams from UBC with those from Amazon Web Services,” said Marianne Schroeder, director of the UBC Cloud Innovation Centre. “It was our great privilege to support the realization of this vision; helping to find a technology solution for complex problems is what we do.” The Centre, which launched right before the pandemic in January 2020, supports challenges that focus on community health and wellbeing. To date, the team has published more than 20 projects including reference architecture and deployment guides all available open source. “While the public cloud as we know it has been around for 15 years, the last few years of innovation at Amazon Web Services have really made genomics research possible in a new way,” said Coral Kennett, who heads up the Centre for Amazon Web Services. “We were able to give Artem access to compute power for pennies a query. We highly encourage the research community to submit their projects and ideas to the Cloud Innovation Centre so that more innovation comes to light benefitting the community.” Reference: “Petabase-scale sequence alignment catalyses viral discovery” by Robert C. Edgar, Jeff Taylor, Victor Lin, Tomer Altman, Pierre Barbera, Dmitry Meleshko, Dan Lohr, Gherman Novakovsky, Benjamin Buchfink, Basem Al-Shayeb, Jillian F. Banfield, Marcos de la Peña, Anton Korobeynikov, Rayan Chikhi and Artem Babaian, 26 January 2022, Nature. DOI: 10.1038/s41586-021-04332-2
Researchers from the UK’s Medical Research Council Research Institutes have unraveled a longstanding mystery in DNA repair mechanisms, potentially enhancing cancer treatments. Their study revealed how the FANCD2-FANCI protein complex detects and initiates the repair of DNA cross-links, utilizing advanced imaging techniques to visualize this process at the molecular level. Researchers from the LMS and LMB have discovered how the D2-I protein complex identifies and repairs DNA damage, a breakthrough that promises to enhance cancer treatments by improving our understanding of DNA repair pathways. This collaboration could pave the way for more effective therapies by targeting the mechanisms that cancer cells use to resist treatment. A collaboration between researchers at the UK’s two core-funded Medical Research Council Institutes—the Laboratory of Medical Sciences (LMS) in London and the Laboratory of Molecular Biology (LMB) in Cambridge—has unraveled a decades-old mystery, potentially leading to improved cancer treatments in the future. The work, which uncovered the basic mechanism of how one of our most vital DNA repair systems recognizes DNA damages and initiates their repair, has eluded researchers for many years. Using cutting-edge imaging techniques to visualize how these DNA repair proteins move on a single molecule of DNA, and electron microscopy to capture how they “lock-on” to specific DNA structures, this research opens the way to more effective cancer treatments. The collaboration between the laboratories of Professor David Rueda (LMS) and Dr Lori Passmore (LMB) has been a brilliant example of how #teamscience can bear fruitful results and underscores the importance of these two institutes in driving forward research that unlocks the fundamental mechanisms of biology which will underpin the future translation of that work into improvements in human health. A single molecule of DNA (not directly visible) is captured using microscopic beads (the large circles). Each of the red, green, or yellow dots moving between the beads represents a FANCD2I-FANCI protein complex sliding along the DNA molecule, monitoring it for damage. Credit: MRC Laboratory of Medical Sciences Unraveling the DNA Repair Mechanism The researchers were working on a DNA repair pathway, known as the Fanconi Anaemia [FA] pathway, which was identified more than twenty years ago. DNA is constantly damaged throughout our lives by environmental factors including UV light from the sun, alcohol use, smoking, pollution, and exposure to chemicals. One way in which DNA becomes damaged is when it is “cross-linked”, which stops it being able to replicate and express genes normally. In order to replicate itself and to read and express genes, the two strands of the DNA double helix first has to unzip into single strands. When DNA is cross-linked, the “nucleotides” (the “steps” in the double-helix ladder of DNA) of the two strands become stuck together, preventing this unzipping. The accumulation of DNA damages including cross-linking can lead to cancer. The FA pathway is active throughout our lives and identifies these damages and repairs them on an ongoing basis. Individuals who have mutations that make this pathway less effective are far more susceptible to cancers. Although the proteins involved in the FA pathway were discovered some time ago, a mystery remained over how they identified the cross-linked DNA and started the process of DNA repair. The team from the MRC LMS sister institution, the LMB in Cambridge, led by Lori Passmore, had previously identified that the FANCD2-FANCI (D2-I) protein complex, which acts in one of the first steps of the FA pathway, clamps onto DNA, thereby initiating DNA repair at crosslinks. However, key questions remained: how does D2-I recognize crosslinked DNA, and why is the D2-I complex also implicated in other types of DNA damage? The research, published in the journal Nature, used a combination of cutting-edge scientific techniques to show that the D2-I complex slides along the double-stranded DNA, monitoring its integrity, and has also elegantly visualized how it recognizes where to stop, allowing the proteins to move and lock together at that point to initiate DNA repair. Advanced Techniques Shed Light on Molecular Interactions Artur Kaczmarczyk and Korak Ray in David Rueda’s Single Molecule Imaging group, working with Pablo Alcón in Lori Passmore’s group, used a state-of-the-art microscopy technique known as “correlated optical tweezers and fluorescence imaging” to explore how the D2-I complex slides along a double-stranded DNA molecule. Using optical tweezers, they could catch a single DNA molecule between two beads, which allowed them to precisely manipulate the DNA and incubate it with chosen proteins. Using fluorescently labeled D2-I and single-molecule imaging, they observed how individual D2-I complexes bind to and slide along DNA, scanning the double helix. They discovered that rather than recognizing the crosslink between the two strands of DNA directly, the FA clamp instead stops sliding when it reaches a single-stranded DNA gap, a region where one of the two strands of DNA is missing. The video shows the FANCD2-FANCI complex clamping to DNA in order to repair it. Credit: MRC Laboratory of Medical Sciences, MRC Laboratory for Molecular Biology Using cryo-electron microscopy, a powerful technique which can visualize proteins at a molecular level, the researchers next determined the structures of the D2-I complex both in its sliding position and stalled at the junction between single-stranded and double-stranded DNA. This revealed that the contacts D2-I makes with this single-stranded–double-stranded DNA junction are distinct from the contacts it makes with double-stranded DNA alone. This allowed them to identify a specific portion of the FANCD2 protein, called the “KR helix” that they showed in their single-molecule imaging experiments is critical for recognizing and stalling at the single-stranded DNA gaps. Working with Guillaume Guilbaud and Julian Sale in the LMB’s PNAC Division, and Themos Liolios and Puck Knipscheer at the Hubrecht Institute, Netherlands, they further showed that the D2-I complex’s ability to stall at these junctions using the KR helix is critical for DNA repair by the FA pathway. When DNA normally replicates in our cells, it unzips the two DNA strands and copies each single strand. This creates a ‘replication fork’ where the original DNA strands are unwound and new double-stranded DNA is formed on each strand. However, when this fork reaches a DNA crosslink, the strands cannot be unzipped, stalling the usual DNA replication process. This stalled replication fork thus contains exposed single-stranded gaps where the DNA has been unwound but not replicated. This research has shown that it is these junctions between single- and double-stranded DNA at the stalled replication fork that the D2-I protein complex latches tightly onto. Implications for Cancer Treatment and Beyond Not only does this allow D2-I complex to bring other FA pathway proteins to the DNA crosslink to initiate repair, but it also anchors the remaining double-stranded DNA, protecting the stalled “replication fork” from enzymes in the cell that would chew up the exposed end of the DNA strand and further damage the DNA. This work has shown that it is DNA structures within the replication fork that stalls as a result of cross-linked DNA, rather than the cross-linked DNA itself, that triggers the D2-I complex to stop sliding and clamp on to DNA to initiate repair. These stalled replication forks appear in many types of DNA damage, explaining the broad role of the D2-I complex in other forms of DNA repair as well as via the FA pathway. Understanding the process of DNA repair, and, importantly, why it fails, holds huge importance as DNA damage is a key factor in many diseases. Critically, many cancer drugs, for example, Cisplatin, work by inducing such serious cellular damage to cancer cells that they stop dividing and die. In such cases, DNA repair pathways—such a vital physiological process in normal life—can be hijacked by cancer cells that use them to resist the effects of chemotherapy drugs. Understanding the mechanistic basis of the first step in the DNA repair pathway may lead to ways of sensitizing patients so that cancer drugs can be more effective in the future. Reference: “FANCD2–FANCI surveys DNA and recognizes double- to single-stranded junctions” by Pablo Alcón, Artur P. Kaczmarczyk, Korak Kumar Ray, Themistoklis Liolios, Guillaume Guilbaud, Tamara Sijacki, Yichao Shen, Stephen H. McLaughlin, Julian E. Sale, Puck Knipscheer, David S. Rueda and Lori A. Passmore, 31 July 2024, Nature. DOI: 10.1038/s41586-024-07770-w This work was funded by UKRI MRC, the Wellcome Trust, the European Research Council, and the EMBO.
Researchers at Boston University have identified a peptide, PACAP, in the brain as a key contributor to heavy alcohol drinking. By inhibiting PACAP in the brain’s BNST area, their study significantly reduced alcohol consumption, suggesting new avenues for treating alcohol addiction. Alcohol ranks as the world’s most widespread addictive substance. In the United States, the annual cost of excessive alcohol consumption amounts to $249 billion, and it leads to roughly 88,000 fatalities each year, along with numerous chronic health conditions and societal problems. Over 14 million individuals in the U.S. suffer from alcohol use disorder, a commonly occurring, chronic, and recurrent condition. Despite its prevalence, this disorder is often inadequately treated, with only three moderately effective drug treatments currently available. Chronic exposure to alcohol has been shown to produce profound neuroadaptations in specific brain regions, including the recruitment of key stress neurotransmitters, ultimately causing changes in the body that sustain excessive drinking. The area of the brain known as the “bed nucleus of the stria terminalis” (BNST) is critically involved in the behavioral response to stress as well as in chronic, pathological alcohol use. Breakthrough Research on Alcohol Addiction Researchers from Boston University Chobanian & Avedisian School of Medicine have identified that a peptide called pituitary adenylate cyclase-activating polypeptide (PACAP), is involved in heavy alcohol drinking. In addition, they have discovered that this peptide acts in the BNST area. Using an established experimental model for heavy, intermittent alcohol drinking, the researchers observed that during withdrawal this model showed increased levels of the stress neuropeptide PACAP selectively in the BNST, compared to the control model. Interestingly, a similar increase was also observed in the levels of another stress neuropeptide closely related to PACAP, the calcitonin gene-related peptide, or CGRP. Both peptides have been implicated in stress as well as pain sensitivity, but their role in alcohol addiction is less established. Findings on PACAP’s Role in Alcohol Addiction The researchers then used a virus in a transgenic model to block the neural pathways containing PACAP that specifically arrive to the BNST. “We found that inhibiting PACAP to the BNST dramatically reduced heavy ethanol drinking,” explained co-corresponding author Valentina Sabino, Ph.D., co-director of the School’s Laboratory of Addictive Disorders as well as professor of pharmacology, physiology & biophysics. According to the researchers, these results provide evidence that this protein mediates the addictive properties of alcohol. “We found a key player, PACAP, driving heavy alcohol drinking, which can be targeted for the development of novel pharmacological therapies,” added co-corresponding author Pietro Cottone, Ph.D., associate professor of pharmacology, physiology & biophysics and co-director of the Laboratory of Addictive Disorders. Reference: “Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) of the Bed Nucleus of the Stria Terminalis Mediates Heavy Alcohol Drinking in Mice” by Lauren Lepeak, Sophia Miracle, Antonio Ferragud, Mariel P. Seiglie, Samih Shafique, Zeynep Ozturk, Margaret A. Minnig, Gianna Medeiros, Pietro Cottone and Valentina Sabino, 1 December 2023, eNeuro. DOI: 10.1523/ENEURO.0424-23.2023 Funding for this study was to grants number AA026051 (PC), AA025038 (VS), and AA024439 (VS) from the National Institute on Alcohol and Alcoholism (NIAAA), the Boston University Undergraduate Research Opportunities Program (UROP), the Boston University Micro and Nano Imaging Facility and the Office of the Director of the National Institutes of Health (S10OD024993).
DVDV1551RTWW78V
ODM pillow factory in Taiwan 》performance-first thinking from development to deliveryChina OEM insole and pillow supplier 》long-term production solutions with flexible volumeTaiwan insole OEM manufacturer 》experience you can count on, quality you can trust